NL-OMON51301尚未招募不适用
Automated speech analysis in psychosis - SPEECH
psychiatrie0 个研究点目标入组 25 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 16 至 64（—）
入选标准
- •1. All participants must give signed informed consent;
- •2. Participants have a psychotic disorder classified according to DSM-5;
- •3. Participants are 16-46 years
排除标准
- •1. Unable to give informed consent to all aspects of the study;
- •2. Unable to speak and be interviewed in Dutch;
- •3. Neurological comorbidities affecting speech, e.g. brain haemorrhage.
研究者
相似试验
进行中（未招募）
1 期
Effects of 5 weeks treatment with dapagliflozin in type 2 diabetes patients on how the hormone insulin acts on sugar uptake in muscles.Study to investigate mitochondrial function and insulin sensitivity in skeletal muscle in subjects with T2DM.EUCTR2016-003991-27-NLAstraZeneca AB26
进行中（未招募）
1 期
COMBIVAS: A trial of rituximab versus rituximab and belimumab for time to remission in ANCA vasculitisANCA-associated vasculitisMedDRA version: 20.1 Level: PT Classification code 10050894 Term: Anti-neutrophil cytoplasmic antibody positive vasculitis System Organ Class: 10021428 - Immune system disordersEUCTR2017-004645-24-GBCambridge University Hospitals NHS Foundation Trust and the University of Cambridge30
已完成
不适用
Selective mutism - A follow up studyselective mutism - speech deficit10002861NL-OMON34793niversitair Medisch Centrum Utrecht100
已完成
2 期
A Phase II/III, Randomized, Single Blinded, Active Controlled Study to Evaluate the Immunogenicity and Safety of inactivated Japanese encephalitis Vaccine in healthy volunteersCTRI/2011/07/001855Bharat Biotech Intl Ltd600
进行中（未招募）
1 期
SYMPHONY-1: A Phase 1b/3 double-blind, randomized, active-controlled, 3-stage, biomarker adaptive study of tazemetostat or placebo in combination with lenalidomide plus rituximab in subjects with relapsed/refractory follicular lymphomaRelapsed/refractory follicular lymphomaMedDRA version: 24.0Level: HLTClassification code 10016903Term: Follicle centre lymphomas, follicular grade I, II, IIISystem Organ Class: 10016903 - Follicle centre lymphomas, follicular grade I, II, IIIEUCTR2019-003333-42-BEEpizyme, Inc; an Ipsen Company568